At a glance
- Originator Santen Pharmaceutical
- Class Antirheumatics
- Mechanism of Action Leukotriene A4 hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 18 May 2004 Suspended - Preclinical for Inflammatory bowel disease in USA (unspecified route)
- 18 May 2004 Suspended - Preclinical for Psoriasis in USA (unspecified route)
- 18 May 2004 Suspended - Preclinical for Rheumatoid arthritis in USA (unspecified route)